查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1983804

流感治療藥物市場：2026-2032年全球市場預測（依劑型、給藥途徑、藥物類別、最終用戶和分銷管道分類）

Influenza Medication Market by Form, Route Of Administration, Drug Class, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，流感治療市場價值將達到 37.9 億美元，到 2026 年將成長至 39.9 億美元，到 2032 年將達到 54.9 億美元，複合年成長率為 5.44%。

主要市場統計數據
基準年 2025 37.9億美元
預計年份：2026年 39.9億美元
預測年份 2032 54.9億美元
複合年成長率 (%) 5.44%

本導言部分全面且策略性地概述了影響現代流感治療決策的臨床因素、劑量形式和操作挑戰。

流感治療領域的特點是臨床創新迅速、監管預期不斷變化以及醫療服務模式發生變革，這些因素共同重新定義了製藥公司、保險公司和醫療服務提供者的策略重點。

對科學、供應鏈和護理路徑的變化進行詳細審查，這些變化正在重塑抗病毒治療模式、獲取模式和相關人員的優先事項。

流感領域正經歷一場變革，這場變革的驅動力來自科學的進步、不斷演進的診療路徑以及對藥品供應和配送韌性的重新重視。具有全新作用機制的新型抗病毒藥物正在改變治療模式，而對快速診斷和門診治療的重新重視也在重塑藥物的處方和分發地點及方式。

本研究將詳細檢驗2025 年價格調整帶來的供應鏈趨勢和籌資策略調整，並找出需要對治療藥物跨境採購和庫存策略進行重組的因素。

2025年新關稅政策的實施將顯著增加跨境藥品供應鏈和籌資策略的複雜性。關稅調整加劇了國際採購的成本影響，促使生產商和經銷商重新評估其生產基地、綜合供應合約和本地庫存策略，以維持服務水準並確保產品流通的穩定性。

將給藥途徑、製劑特性、藥物類別差異、分銷管道和最終用戶路徑與策略決策因素聯繫起來的詳細細分見解。

詳細的細分觀點揭示了每種給藥途徑、劑型、藥物類別、分銷管道和最終用戶環境的獨特臨床、商業性和營運影響，這反過來又有助於制定產品定位和通路策略。

我們根據全面的區域觀點製定打入市場策略，協調美洲、歐洲、中東和非洲以及亞太地區在監管、分銷和臨床實踐方面的差異。

區域趨勢持續對全球流感治療市場的准入、監管和採用模式產生決定性影響，因此需要製定細緻入微的區域策略，使臨床證據與分銷能力和支付方期望相一致。

投資那些在研發、製造、數位化夥伴關係以及以通路為中心的商業化模式方面實現差異化的公司的策略行動和能力。

在流感治療領域，企業行為和策略立場決定了藥物發現、開發、生產和商業化整體的競爭動態。

為領導者提供可操作且優先考慮的建議，以協調臨床差異化和供應彈性、通路最佳化以及基於證據的打入市場策略。

產業領導者應採取一系列切實可行的措施，將臨床差異化、營運韌性和通路最佳化相結合，以創造價值並支持改善患者預後。

檢驗採用高度透明、以證據為基礎的調查方法來驗證我們的發現和建議，該方法結合了專家訪談、系統性的二手研究和情境檢驗驗證。

本報告的調查方法結合了多方面的證據整合、與專家的對話以及系統性的檢驗，以得出可靠且可操作的結論。

一項果斷的整合，強調在臨床創新、供應彈性和通路策略方面的整合執行，以確保患者能夠獲得治療並帶來明顯的益處。

總之，流感治療生態系統正處於一個轉折點，科學創新、通路演變和供應韌性相互交織，重新定義了整個價值鏈上相關人員的策略挑戰。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：流感治療市場：以劑型分類

  • 注射藥物
  • 吸入用粉末
  • 懸浮液
  • 藥片
    • 金剛烷胺
    • 巴洛沙韋酯
    • 奧司他韋
    • 金剛烷胺

第9章：流感治療市場：依給藥途徑分類

  • 吸入
  • 靜脈
  • 口服
    • 懸浮液
    • 藥片

第10章：流感治療市場：依藥物類別分類

  • 核酸內切酶抑制劑
  • M2離子通道抑制劑
    • 金剛烷胺
    • 金剛烷胺
  • 神經氨酸酶抑制劑
    • 奧司他韋
    • 帕拉米韋
    • 扎那米韋

第11章 流感治療市場：依最終使用者分類

  • 居家醫療
  • 醫院
  • 門診部

第12章：流感治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章：流感治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 流感治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 流感治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國流感治療市場

第17章：中國流感治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • AstraZeneca PLC
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • Cocrystal Pharma, Inc.
  • CSL Limited
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Lupin Limited
  • Merck & Co., Inc.
  • NATCO Pharma Limited
  • Novartis AG
  • Pfizer Inc.
  • Qiagen NV
  • Sandoz International GmbH
  • Sanofi SA
  • Shionogi & Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Pharmaceuticals, Inc.
Product Code: MRR-F6513A06BE18

The Influenza Medication Market was valued at USD 3.79 billion in 2025 and is projected to grow to USD 3.99 billion in 2026, with a CAGR of 5.44%, reaching USD 5.49 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.79 billion
Estimated Year [2026] USD 3.99 billion
Forecast Year [2032] USD 5.49 billion
CAGR (%) 5.44%

A comprehensive and strategic introduction framing clinical drivers, delivery modalities, and operational imperatives that shape modern influenza therapeutic decision-making

The influenza therapeutic environment is characterized by rapid clinical innovation, evolving regulatory expectations, and shifting patterns of care delivery that together redefine strategic priorities for manufacturers, payers, and providers.

This summary synthesizes the current clinical imperatives-such as timely antiviral initiation, resistance monitoring, and outpatient management trends-alongside the operational realities that shape access and uptake. It highlights how advances in drug classes, delivery modalities, and distribution channels are intersecting with public health preparedness and seasonal demand variability. By placing clinical evidence, supply chain considerations, and stakeholder incentives in one coherent narrative, the introduction equips decision-makers with a holistic vantage point from which to assess risk, prioritize investment, and refine go-to-market planning.

Throughout the report, emphasis is placed on translating clinical differentiation into operational levers: formulary positioning, hospital stocking protocols, and outpatient prescribing workflows. The interplay between pharmacological attributes and channel capabilities is explored to identify friction points and opportunities for adoption. Ultimately, this introduction lays the foundation for a structured exploration of transformative shifts, tariff impacts, segmentation realities, regional dynamics, competitive behaviors, and practical recommendations that follow.

An in-depth review of scientific, supply chain, and care pathway shifts that are reshaping antiviral treatment patterns, access models, and stakeholder priorities

The influenza landscape is undergoing transformative shifts driven by scientific advances, care pathway evolution, and a renewed focus on resilience in supply and delivery. Emerging antiviral classes with novel mechanisms of action are changing treatment paradigms, while the renewed emphasis on rapid diagnostics and outpatient care is reshaping where and how therapies are prescribed and dispensed.

Concurrently, manufacturing agility and strategic sourcing have moved to the forefront as organizations seek to mitigate disruption risks. The convergence of improved inhalation and oral formulations, coupled with targeted molecular therapies, is prompting payers and providers to reassess treatment algorithms. As a result, stakeholders are increasingly prioritizing real-world effectiveness and resistance profiles over traditional efficacy endpoints, thereby influencing formulary decisions and clinical guidelines.

Additionally, digital health enablers and evolving distribution channels are facilitating more patient-centric models of care. Remote consultations, pharmacy home delivery services, and integrated care pathways support earlier initiation of therapy, which can materially affect demand patterns and stock management. Taken together, these shifts require companies to adopt integrated commercialization approaches that align R&D pipelines, regulatory strategies, and channel engagement to capture and sustain clinical and market relevance.

A detailed examination of 2025 tariff-driven supply chain dynamics and procurement adaptations that are reshaping cross-border sourcing and inventory strategies for therapeutics

The introduction of new tariff policies in 2025 has introduced material complexity into cross-border pharmaceutical supply chains and procurement strategies. Tariff adjustments have amplified the cost implications of international sourcing, prompting manufacturers and distributors to reassess production footprints, aggregate supply agreements, and local inventory strategies in order to preserve service levels and maintain predictable product flows.

In response, some organizations have accelerated localization of critical manufacturing steps or qualified alternate suppliers to reduce exposure to tariff volatility. Others have renegotiated commercial terms with downstream partners to distribute incremental costs more equitably across the value chain. These adaptations have emphasized the importance of flexible contracting, dual-sourcing, and inventory buffers to absorb tariff-induced cost movements without disrupting clinical availability.

Moreover, procurement teams and policy stakeholders are re-evaluating tender and purchasing frameworks to reflect new landed-cost realities. The practical consequence for market participants is a heightened emphasis on scenario planning and stress testing for international logistics, as well as a renewed focus on regulatory harmonization that can simplify cross-border movement of finished dosage forms and APIs. Ultimately, the tariff landscape has underscored the strategic value of supply chain resilience as an integral component of commercial planning.

Detailed segmentation insights connecting route of administration, formulation nuances, drug class differentiation, distribution channels, and end-user pathways to strategic decision levers

A granular segmentation lens reveals distinctive clinical, commercial, and operational implications across routes, forms, drug classes, distribution channels, and end-user settings that collectively inform product positioning and channel strategy.

When evaluating Route Of Administration, stakeholders must consider Inhalation as a modality that supports rapid pulmonary delivery for targeted effect, Intravenous as a critical option for severe cases and inpatient settings, and Oral treatments that cater to outpatient convenience; within Oral, the differentiation between Suspension and Tablet formulations affects adherence, pediatric dosing, and dispensing workflows. In terms of Form, Injection remains central to hospitalized care pathways while Powder Inhaler supports ambulatory administration; Suspension formulations enable flexible dosing for children and patients with swallowing difficulties, and Tablet formats encompass a portfolio that includes Amantadine, Baloxavir Marboxil, Oseltamivir, and Rimantadine with important implications for prescribing preferences and stock management.

From a Drug Class perspective, Endonuclease Inhibitors represent a newer mechanism with implications for resistance management and combination strategies; M2 Ion Channel Inhibitors encompass Amantadine and Rimantadine and carry a specific historical resistance and safety profile that limits their contemporary use in certain contexts; Neuraminidase Inhibitors include Oseltamivir, Peramivir, and Zanamivir and remain a cornerstone of current antiviral toolkits, particularly where early administration is feasible. Distribution Channel analysis highlights Hospital Pharmacy as the fulcrum for inpatient care and emergency treatment, Online Pharmacy as an accelerating conduit for direct-to-patient access and convenience, and Retail Pharmacy as the primary patient-facing touchpoint for seasonal demand and pharmacist-led counseling. Lastly, End User segmentation underscores that Home Care is increasingly important for early treatment initiation and adherence support, Hospitals represent acute care and severe case management, and Outpatient Clinics serve as critical points for diagnosis, initiation of therapy, and follow-up-each setting shaping stocking decisions, packaging choices, and patient education needs.

Taken together, these interlocking segmentation dimensions guide commercialization choices, from packaging and dispensing formats to channel partnerships and targeted medical affairs programs, and should be considered holistically when designing launch and lifecycle strategies.

Comprehensive regional perspective that aligns regulatory, distribution, and clinical practice differences across the Americas, Europe Middle East & Africa, and Asia-Pacific to inform market entry strategies

Regional dynamics continue to exert a defining influence on access, regulation, and adoption patterns across the global influenza therapeutic landscape, requiring nuanced regional strategies that align clinical evidence with distribution capabilities and payer expectations.

In the Americas, established outpatient infrastructures, integrated retail pharmacy networks, and strong home-care services create opportunities for orally administered antivirals and pharmacy-led initiation pathways; diagnostic availability and payer coverage models further shape adoption dynamics. In Europe, Middle East & Africa, variable regulatory pathways and heterogeneous reimbursement systems necessitate flexible launch approaches that account for national formularies and local clinical guidelines, while some markets in the region are investing in expanded inpatient capacities and supply chain modernization to strengthen pandemic preparedness. In the Asia-Pacific region, fast-moving adoption of digital health tools, rising investments in local manufacturing, and a high prevalence of community-based care models support diversified distribution strategies that can emphasize both inhalation and oral solution access depending on local prescribing habits.

Across all regions, stakeholders should calibrate product positioning to reflect differences in diagnostic infrastructure, pharmacist scope of practice, and payer arrangements. Moreover, regional policy initiatives focused on antimicrobial stewardship and resistance surveillance are increasingly shaping therapeutic choice and formulary decisions. Consequently, a regionally adaptive approach-one that aligns clinical messaging, supply strategies, and channel engagement with local system realities-will be essential for sustained access and uptake.

Strategic company behaviors and capability investments that are driving differentiation across R&D, manufacturing, digital partnerships, and channel-focused commercialization models

Company behaviors and strategic postures are defining competitive dynamics across discovery, development, manufacturing, and commercialization activities in the influenza therapeutics arena.

Leading firms are prioritizing portfolios that balance near-term commercial opportunities with longer-term investments in novel mechanisms and combination therapies. Strategic partnerships between biologics developers, specialty manufacturers, and diagnostic providers are accelerating integrated value propositions that tie antiviral therapies to rapid point-of-care testing and patient triage services. On the manufacturing front, firms are investing in modular and multi-site production capabilities to enhance flexibility and reduce single-source vulnerabilities, while quality and supply continuity programs are being elevated to board-level attention.

Commercially, companies are refining segmentation-driven go-to-market models that tailor messaging to hospital formulary committees, retail pharmacy networks, and digital health platforms. Medical affairs teams are increasingly central to lifecycle management, providing evidence generation and real-world outcomes studies that support positioning in the face of resistance concerns and comparative effectiveness questions. Some organizations are also exploring differentiated packaging, patient support solutions, and adherence technologies to strengthen outpatient persistence and therapeutic value. Collectively, these company-scale actions are reshaping competitive advantage from purely product-centric differentiation toward integrated solutions that span diagnostics, supply robustness, and channel-enabled patient access.

Actionable and prioritized recommendations for leaders to align clinical differentiation with supply resilience, channel optimization, and evidence-driven market access strategies

Industry leaders should adopt a set of pragmatic, actionable moves that align clinical differentiation with operational resilience and channel optimization to capture value and support improved patient outcomes.

First, embed resistance surveillance and real-world effectiveness endpoints into development and post-launch evidence plans so that therapeutic positioning responds to evolving clinical practice. Second, pursue supply chain diversification and local qualification of key suppliers to minimize exposure to tariff and logistics shocks; dual-sourcing and contingency inventories should be part of scenario planning. Third, design packaging and dosing formats that reflect end-user needs across home care, hospitals, and outpatient clinics, ensuring that pediatric and geriatric usability considerations are prioritized. Fourth, cultivate partnerships with diagnostic providers and digital platforms to accelerate timely initiation of therapy and to create bundled care pathways that improve adherence and outcomes. Fifth, tailor regional market access strategies to local reimbursement frameworks, aligning clinical dossiers with payer evidence requirements and engaging early with health technology assessment bodies when applicable.

Finally, invest in targeted commercial capabilities-such as pharmacy engagement teams, digital patient support, and outcome-based contracting expertise-that can translate clinical value into formulary acceptance and sustained uptake. By implementing these recommendations, leaders can minimize operational risk while enhancing the clinical and commercial performance of influenza therapeutics.

A transparent, evidence-driven methodology integrating primary expert interviews, systematic secondary research, and scenario triangulation to validate findings and recommendations

The research methodology underpinning this report combines multi-source evidence synthesis, expert engagement, and systematic validation to ensure robust and actionable conclusions.

Primary research included in-depth interviews with clinicians, pharmacy directors, supply chain executives, and payer representatives to ground interpretations of clinical practice, formulary behavior, and procurement dynamics. Secondary research involved systematic review of peer-reviewed clinical literature, regulatory guidance documents, public health advisories, and product labeling to corroborate mechanism-of-action insights and safety profiles. The analysis also integrated operational data on distribution channels and care settings to link clinical attributes with real-world execution challenges.

Findings were triangulated through cross-functional workshops and sensitivity analysis to test assumptions and surface alternative scenarios. Where uncertainties existed-such as evolving resistance trends or policy shifts-clear caveats were included and methodological choices were documented to support transparency. The result is a methodological approach that prioritizes evidence-backed interpretation, stakeholder validation, and scenario-aware recommendations to inform both near-term tactical choices and longer-term strategic planning.

A conclusive synthesis emphasizing integrated execution across clinical innovation, supply resilience, and channel strategies to secure access and demonstrable patient benefit

In conclusion, the influenza therapeutic ecosystem is at an inflection point where scientific innovation, channel evolution, and supply resilience converge to redefine strategic imperatives for stakeholders across the value chain.

The synthesis presented here underscores that successful programs will marry clinical differentiation with operational foresight: aligning novel mechanisms and user-friendly formulations with robust distribution strategies and evidence-generation plans. Regional nuances and tariff-driven supply pressures add layers of complexity that necessitate adaptive manufacturing footprints and close collaboration with payers and providers. Companies that proactively integrate diagnostic partnerships, strengthen pharmacy engagement, and prioritize real-world evidence generation will be better positioned to demonstrate value and secure sustainable access in diverse care settings.

Ultimately, the path forward is one of integrated execution-where R&D choices, commercial models, and supply chain strategies are orchestrated to accelerate timely access, manage resistance risk, and deliver measurable benefits for patients and health systems alike.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Influenza Medication Market, by Form

  • 8.1. Injection
  • 8.2. Powder Inhaler
  • 8.3. Suspension
  • 8.4. Tablet
    • 8.4.1. Amantadine
    • 8.4.2. Baloxavir Marboxil
    • 8.4.3. Oseltamivir
    • 8.4.4. Rimantadine

9. Influenza Medication Market, by Route Of Administration

  • 9.1. Inhalation
  • 9.2. Intravenous
  • 9.3. Oral
    • 9.3.1. Suspension
    • 9.3.2. Tablet

10. Influenza Medication Market, by Drug Class

  • 10.1. Endonuclease Inhibitors
  • 10.2. M2 Ion Channel Inhibitors
    • 10.2.1. Amantadine
    • 10.2.2. Rimantadine
  • 10.3. Neuraminidase Inhibitors
    • 10.3.1. Oseltamivir
    • 10.3.2. Peramivir
    • 10.3.3. Zanamivir

11. Influenza Medication Market, by End User

  • 11.1. Home Care
  • 11.2. Hospitals
  • 11.3. Outpatient Clinics

12. Influenza Medication Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Influenza Medication Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Influenza Medication Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Influenza Medication Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Influenza Medication Market

17. China Influenza Medication Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Agilent Technologies, Inc.
  • 18.7. AstraZeneca PLC
  • 18.8. Bio-Rad Laboratories, Inc.
  • 18.9. Bristol-Myers Squibb Company
  • 18.10. Cocrystal Pharma, Inc.
  • 18.11. CSL Limited
  • 18.12. Daiichi Sankyo Company, Limited
  • 18.13. Eli Lilly and Company
  • 18.14. F. Hoffmann-La Roche AG
  • 18.15. GlaxoSmithKline PLC
  • 18.16. Lupin Limited
  • 18.17. Merck & Co., Inc.
  • 18.18. NATCO Pharma Limited
  • 18.19. Novartis AG
  • 18.20. Pfizer Inc.
  • 18.21. Qiagen N.V.
  • 18.22. Sandoz International GmbH
  • 18.23. Sanofi SA
  • 18.24. Shionogi & Co., Ltd.
  • 18.25. Sun Pharmaceutical Industries Ltd.
  • 18.26. Takeda Pharmaceutical Company Limited
  • 18.27. Teva Pharmaceutical Industries Ltd.
  • 18.28. Viatris Inc.
  • 18.29. Zydus Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INFLUENZA MEDICATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INFLUENZA MEDICATION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INFLUENZA MEDICATION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA INFLUENZA MEDICATION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INFLUENZA MEDICATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY POWDER INHALER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY POWDER INHALER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY POWDER INHALER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY BALOXAVIR MARBOXIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY BALOXAVIR MARBOXIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY BALOXAVIR MARBOXIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ENDONUCLEASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ENDONUCLEASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ENDONUCLEASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY PERAMIVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY PERAMIVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY PERAMIVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ZANAMIVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ZANAMIVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ZANAMIVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. GCC INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GCC INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 186. GCC INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 187. GCC INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. GCC INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 189. GCC INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 190. GCC INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 191. GCC INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 192. GCC INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. GCC INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. G7 INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. G7 INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 216. G7 INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 217. G7 INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. G7 INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 219. G7 INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 220. G7 INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 221. G7 INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 222. G7 INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. G7 INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. NATO INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. NATO INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 226. NATO INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 227. NATO INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. NATO INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 229. NATO INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 230. NATO INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 231. NATO INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 232. NATO INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. NATO INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA INFLUENZA MEDICATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)